

Index

- ABC, *see* accelerated blood clearance
- accelerated blood clearance (ABC) 57
- AFM, *see* atomic force microscopy
- therapeutic agents 71, 122, 250, 294, 297, 300
- antibacterial activity 361–363, 367, 369
- anticancer drugs 35, 40, 55, 120–122, 152–153, 172–173, 199–200, 204–206, 211, 241, 304
- antigen presenting cells (APCs) 322–324, 329, 337
- antigens 202, 205, 322, 324–325, 327, 329–330, 334–339, 437
- antimicrobial activity 130–131, 157, 357–358, 362, 367
- antimicrobials 358–359, 367, 370–371
- antioxidants 132–133
- APCs, *see* antigen presenting cells
- apoptosis 128, 132, 201–202, 204, 332–333, 527, 530–531
- atomic force microscopy (AFM) 5, 124, 529
- bacteria 131, 335, 357, 359, 361–363, 365, 369
- bactericidal effect 360–361, 363–364
- batchwise variation 338, 563, 565–566
- BBB, *see* blood-brain barrier
- biodegradable polymers 195, 203, 205, 207, 209, 211, 213, 371, 562
- biofilms 364–365, 368, 371
- biomarker 436–439, 441, 531
- blood-brain barrier (BBB) 71, 106, 200, 214, 369, 371, 472
- blood glucose levels 207, 211–212, 477
- blood pool agents (BPAs) 473
- bovine serum albumin (BSA) 204, 210–211, 215, 394, 472
- BPAs, *see* blood pool agents
- BSA, *see* bovine serum albumin
- buckminsterfullerene 5–6, 115–116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 362
- buckyballs 5, 115, 118, 434–435, 524
- cancer 41, 48–49, 52–53, 60, 68, 71, 155, 293–294, 303–305, 422, 426, 432, 467, 474, 487
- gastric 68, 202
- cancer biomarkers 436–437
- cancer cells 42, 46, 63, 121, 129, 153–157, 272, 297, 322, 325, 438, 468, 484, 563
- cancer immunology 322–323
- cancer immunotherapy 321–322, 324–325, 327, 329, 331, 333
- cancer therapy 38, 122, 195, 200, 249, 272–273, 321, 436
- cancer tissues 40–41, 49, 54, 321
- carbon black (CB) 17, 337, 371, 528–529, 532
- carbon nanotubes 5, 17, 122, 147–148, 150, 152, 154, 156, 158, 364, 389–390, 465, 524
- carboxyfullerenes 130–131, 363

- CB, *see* carbon black
- cell membrane 39–40, 123,
131–132, 152–153, 177, 200,
360, 363, 367, 393, 401,
521–522, 524, 527, 531
- cells 150, 153–155, 253–254,
302, 304, 322, 324, 326–329,
332–334, 337, 339, 391,
395–401, 483, 520–522
myeloid-derived suppressor
323
- cellular uptake 46, 123, 148,
151–152, 154, 280, 302, 326,
339, 469
- central nervous system (CNS)
200, 372
- chemical species 303, 358
reactive 7, 22
- chemical vapor deposition 296,
435
- chemotherapeutic agents 62
- chemotherapy 122, 129
- chitosan particles 213–214
- circulation time 55–57, 70, 201,
203, 252, 279, 299, 372,
470–471
- clinical trials 36, 44, 50, 58–59,
61–63, 65–71, 121, 254, 294,
304, 335, 559–560, 562, 565,
568
- CNS, *see* central nervous system
- colloidal dispersions 20
- composite materials 248–249
- computed tomography (CT) 465,
470, 476–477, 479
- conjugates 47, 120, 122, 124–125,
127, 129, 134, 153, 155,
174–175, 279, 297, 359, 366,
401
- contrast agents 293, 432, 466,
471, 473, 475, 478–479, 484
vivo X-ray CT scan 470
- copolymers 54, 197, 209, 366
- corneal tissues 178, 396
- CT, *see* computed tomography
- cyclodextrins 118–119, 175, 275
- DCs, *see* dendritic cells
- DDSs, *see* drug delivery systems
oral 176, 199
- delivery agents 202–203, 304,
364, 366, 398–399, 401
- dendrimeric formulations 174,
178, 180, 488, 559
- dendrimers 25, 124, 167–181,
274, 327–328, 367, 389, 398,
401, 468, 475, 488
- dendritic cells (DCs) 322,
324–327, 329, 339, 527–528
- devices, microfluidic 430, 443,
565
- dexamethasone 209, 242, 248,
403
- diffusion 105, 197, 210, 212, 521
- dip-pen nanolithography (DPN)
402
- dispersions 16, 22, 102–103, 423
- DLS, *see* dynamic light scattering
- doxorubicin 43, 46, 52, 56, 59, 61,
67, 70–71, 104–105, 120–121,
129, 154, 200–201, 206, 559
free 43, 59, 61, 105, 120, 129,
333
- DPN, *see* dip-pen nanolithography
- drug delivery 38, 42, 117, 120,
196, 200, 246, 271, 293, 296,
298–299, 303–305, 358, 360,
403–404
anticancer 40
devices 389
ocular 181
- drug delivery systems (DDSs)
35, 39–41, 43, 97, 119–121,
148–150, 167, 173, 177–179,
181, 207–215, 246, 254, 277,
300–301

- drug molecules 37, 51, 98–100, 104–105, 120, 148, 172, 179–180, 199, 205, 214, 246–248, 274, 278, 301
 - bound 247
- drug payload 35, 40, 45, 47, 50–51, 55, 98–99, 104–105, 119
- drug release 53–54, 72, 196–197, 208, 242, 274, 280
- drugs 69–71, 97–101, 104–105, 154, 178–180, 196–197, 205–206, 214–215, 246–248, 250, 273, 280, 366, 393, 437
 - chemotherapeutic 62, 323
 - orphan 62, 68
 - thermolabile 100, 102, 435
- dynamic light scattering (DLS) 103, 338, 563–564

- EE, *see* encapsulation efficiency
- EGF, *see* epidermal growth factor
- encapsulated drug 45, 51, 200, 206, 208, 214, 274–275, 277, 367, 395, 563
- encapsulation 63, 71, 99, 172, 196, 199, 202, 208–209, 212, 299, 367, 557
- encapsulation efficiency (EE) 62, 104, 206, 209–211, 369, 565
- environment, chemical 172, 523
- enzymes 35, 38, 46–47, 49, 125–126, 155, 203–204, 206, 272, 274–275, 401–402, 425, 429, 526
- epidermal growth factor (EGF) 43, 52, 152, 174–175, 201, 272–273, 303, 323, 438, 467
- Escherichia coli* 130, 358, 360–362, 364, 367, 369–370, 443
- external magnetic field 153, 155, 278, 293, 295, 305, 331, 398, 442–443, 485

- FA, *see* folic acid
- fluorescence 22, 440–442, 476, 478–479, 481, 484
- folic acid (FA) 42, 153–154, 156, 174, 272, 280, 299, 303, 437, 468–469, 488
- free drug 59, 121, 129–130, 154, 196, 368, 371
- fullerenes 5, 16, 25, 115–117, 119–123, 125–133, 135, 524–526
- fullerenols 128, 132, 134
- fusion 46, 335, 367

- GCEs, *see* glassy carbon electrodes
- gelatin 196, 201, 214, 394, 396
- gene delivery 23, 123, 175, 201
- gene silencing 155, 249
- genetic materials 23, 35, 123, 154, 176, 195, 202, 280, 304–305, 334, 393, 401, 404
- genotoxicity 131, 254, 524, 530, 533
- GF, *see* growth factor
- GFP, *see* green fluorescent protein
- glassy carbon electrodes (GCEs) 428
- gold 17, 20, 278, 294, 297, 300–301, 328, 338, 402, 430, 466, 477, 484–485, 524
- gold nanostars 426–427, 477
- green fluorescent protein (GFP) 278, 305, 399, 440
- growth 1, 42, 47, 53, 204, 280, 322–323, 327, 332, 366, 370, 391, 395–397, 404, 523
 - cellular 393, 395–396, 398
- growth factor (GF) 40, 43, 152, 174–175, 201–202, 272–273, 303, 322–323, 391, 393, 395, 398–399, 404, 467, 530

- HeLa cells 48, 129, 151, 153–155, 278, 280, 394, 474, 481, 484, 489, 562

- high-pressure homogenization (HPH) 100–101
- high-speed stirring 100–102
- HIV, *see* human immunodeficiency virus
- HPH, *see* high-pressure homogenization
- HPV, *see* human papilloma virus
- human immunodeficiency virus (HIV) 125–126, 335, 426, 428, 559
- human papilloma virus (HPV) 335, 559
- human umbilical vein endothelial cells (HUVECs) 330, 393, 396
- HUVECs, *see* human umbilical vein endothelial cells
- hydrolysis 205–206, 211, 214, 300
- hydrophilic 35, 39, 46, 54, 119, 209, 246, 248, 366–367
 - drugs 36, 39, 63, 99–100, 103
 - molecules 39–40, 105, 119, 248, 296, 489, 534
- hydroxyls 526–527
- immune response 155–156, 323–325, 329–332, 334, 336, 338–339, 399, 527
- immunoconjugates 122
- immunoliposomes 38, 42–43
- immunosuppression 322–323
- immunotherapy 155, 321, 328, 339
- insulin 47, 199, 207–208, 211–213
- integrin receptors 437, 439, 467, 469
- intramuscular 66, 210, 335–337
- intratracheal instillation 528–529
- intratumoral 45–46, 276, 332, 470–471
- intravenous administration
 - 55–56, 59–60, 63–65, 67–68, 105, 174–175, 204, 206, 211, 251, 254, 332–333, 467–468, 470–472, 475
- iron 294, 296–297, 441, 486, 526
- layer-by-layer (LbL) 360, 393
- LbL, *see* layer-by-layer
- LDCs, *see* lipid drug conjugates
- leakage 50, 98, 102–103, 473
- lipid bilayers 35–37, 39, 44, 46, 49, 52–53, 57–58, 66, 70, 119, 203, 367, 520, 522
- lipid composition 50–51, 59–60, 62, 69
- lipid constituents 61–62, 64, 67–68, 70, 103
- lipid drug conjugates (LDCs) 97–100, 104
- lipids 36–37, 46–47, 49–50, 52, 57–58, 62, 67, 70, 97–100, 102–104, 131, 360, 363, 520, 530
 - melted 100–101
 - solid 99
- lipophilic drugs 99
- lipoproteins 56–57
- liposomal technology 45, 55
- liposomes 35–58, 60, 62, 64, 66–68, 70, 72, 97–98, 104–106, 328–331, 333, 335, 365, 367–369, 390
 - active 398
 - anionic 45, 56
 - bigger 56
 - cationic 44–45, 56, 328
 - lipid 203, 393
 - multivesicular 63, 66–67
 - smaller 56–57
 - synthesis of 36, 45
 - theranostic 38–39

- liver 38, 41, 55, 57, 173, 175,
208, 211, 251–253, 368–369,
403, 470–471, 473–474, 476,
489–490
- localized surface plasmon
resonance (LSPR) 420–424,
426
- LSPR, *see* localized surface
plasmon resonance
- macromolecules 40, 42, 167, 274,
393, 522, 526, 530, 563
- magnetic drug 293
- magnetic drug targeting (MDT)
293, 304
- magnetic nanoparticles 293–294,
296, 298, 300, 302, 304, 306,
487
- magnetic resonance imaging (MRI)
129, 293, 296, 298–299, 403,
469, 476–477, 481, 486, 488
- MDSCs, *see* myeloid-derived
suppressor cells
- MDT, *see* magnetic drug targeting
- mesenchymal stem cells (MSCs)
273, 395–397, 400, 403, 486
- mesoporous silica nanoparticles
271, 274, 276, 278, 280
- micelles 134, 299, 329, 332, 390,
432
- microbes 157, 361, 365–367
- micro-organisms 357–361, 443
- mitochondrial membrane 132,
273, 363, 527–528
- molar ratio 47, 49, 51, 59–62,
64–66, 69–71, 175, 336, 395,
471, 475
- molecular machines 2, 7–8
- molecular structure 6, 118–121,
123–126, 128, 130–131,
133–134, 208, 247, 521
- molecular weight 71, 167, 205,
208–209, 212, 298, 362, 488
- molecules 38, 47, 116–119,
127–129, 134–135, 150,
154–155, 168, 176, 279–280,
404, 428–430, 435–436, 471,
473
- dendrimers and drug 172
- hydrophobic 35, 39, 168, 172,
248
- initiator 198–199
- longboat-shaped 154
- single 124, 425–426
- mouse tumor model 333, 467,
469, 472, 476
- MRI, *see* magnetic resonance
imaging
- MSCs, *see* mesenchymal stem cells
- myeloid-derived suppressor cells
(MDSCs) 323, 331, 333–334
- nanofibers 17, 391–392, 396
- nanolithography, dip-pen 402
- nanomedicine research 557, 560,
563
- nanomedicines 2, 35, 42, 72, 167,
176, 195, 199–200, 471, 490,
557, 559–563, 565–568
- nanoparticles-in-microsphere oral
system (NiMOS) 202
- nanoscale 2, 8, 13, 15–18, 147,
195, 435, 465, 519, 565
- dimensions 2–3, 13–14, 17–18,
295, 436
- materials 13, 16, 167, 331, 419,
557, 568
- nanostuctured lipid carriers
(NLCs) 97–101, 104
- NDC, *see* nanoparticle-drug
conjugate
- neural stem cells (NSCs) 396
- NiMOS, *see* nanoparticles-in-
microsphere oral system
- NLCs, *see* nanostuctured lipid
carriers

- NSCs, *see* neural stem cells
 NSET, *see* nanoparticle surface-energy transfer
- oral delivery 176, 199, 202, 370
 oral drug delivery 199
 oral gene delivery 202
 organs 55, 208, 211, 252, 359, 369, 404–405, 439, 471, 476, 534, 561
 oxidative stress 123, 157, 204, 361–362, 364, 476, 524, 526–527, 533
- pancreatic cancers 47, 68
 particle size 14, 58, 106, 197, 205, 279–280, 327, 339, 422, 424, 488, 520–523, 532, 565
 PBS, *see* phosphate buffered saline
 penicillin 199, 357–359, 368
 peptides 23, 38, 46, 150–151, 174, 199, 201, 205, 249–251, 280, 303–305, 325, 330–331, 392, 488
 pharmacokinetics 105, 180, 294
 phosphate buffered saline (PBS) 278–280, 297, 470, 475
 photoacoustic imaging 432, 440, 476, 478–480, 484–485
 physicochemical properties 35, 42, 58, 298, 362, 391, 419, 465, 487, 563, 565–566
 platforms, sensitive detection 47, 426, 429, 436
 polymeric materials 177, 195
 polymeric nanoparticles 195–196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 390
 polymerosomes 392–393
 polymers 50, 53, 195–196, 198–199, 203, 205, 208–209, 249, 272–274, 293–294, 298, 390–391, 393, 402, 404
- proliferation, uncontrolled cell 322
 prostate-specific antigen (PSA) 426–427, 437
 protein corona 522–523, 526
 proteins 56, 61, 155, 303–304, 322, 325, 334–335, 436, 440–441, 487, 490, 520, 522–523, 530, 561
 molecules 522–523
 PSA, *see* prostate-specific antigen
- QC, *see* quality control
 QDs, *see* quantum dots
 quality control (QC) 563
 quantum dots (QDs) 13–17, 20, 22, 25, 152, 389, 395, 402, 440–441, 465, 479–481, 527
- rat bone marrow stromal cells (RBMSCs) 403
 RBMSCs, *see* rat bone marrow stromal cells
 reactive oxygen species (ROS) 121, 123, 128–129, 132, 134, 204, 361, 363, 476, 526–527, 530–531
 receptors 38, 40, 42, 44, 71, 134, 299, 303, 324, 328, 337, 468–469, 521, 524, 530
 cell membrane-bound 521, 523–524, 530
 regenerative medicine 389–398, 400, 402, 404
 respiratory tract infection (RTI) 358, 365, 367
 ROS, *see* reactive oxygen species
 RTI, *see* respiratory tract infection
- SBF, *see* simulated body fluid
 scaffolds 122, 178, 389–393, 395–396, 398–399, 404, 471
 scanning tunneling microscope (STM) 4–5, 8

- sensors 401, 432, 436–437, 443
 - optical 395, 439–440
- SERS, *see* surface-enhanced Raman scattering
- SGF, *see* simulated gastric fluid
- side effects 61, 64, 69, 106, 127, 129–130, 178, 358, 365, 368, 371, 558
- silica 115, 241–243, 248, 279, 294, 300, 328, 364, 403, 424, 473, 477, 489
- silver 19–20, 294, 358–361, 420, 430, 484, 524
- silver nanoparticles 7
- simulated body fluid (SBF) 241, 278–279, 395
- simulated gastric fluid (SGF) 253, 279
- single-walled carbon nanotubes 6, 331, 481
- SLNs, *see* solid lipid nanoparticles
- solid lipid nanoparticles (SLNs) 97–106, 253, 368–369
- solid tumors 53, 63, 71, 558
- solvent evaporation 197, 208–209, 211–212, 215
- SPR, *see* surface plasmon resonance
- stealth 37, 327
- STM, *see* scanning tunneling microscope
- surface charge 44, 56, 58, 167, 175, 177–178, 297, 339, 520–523, 526
- surface chemistry 42, 56, 174, 252, 279, 298, 392
- surface coverage 244–245, 296, 298
- surface-enhanced Raman scattering (SERS) 425, 476, 484
- surface functionalization 119, 150, 176, 195, 205–206, 215, 294, 326, 338, 372, 393, 435, 519, 563
- surface ligands 38, 524
- surface plasmon resonance (SPR) 420, 425
- surface properties 167, 248, 519–520
- sustained-release pattern 98, 174, 206, 210
- TAAs, *see* tumor-associated antigens
- TAMs, *see* tumor-associated macrophages
- targeted drug delivery 305
- T-cell receptors (TCRs) 322, 330–331, 337
- TCRs, *see* T-cell receptors
- TDLNs, *see* tumor-draining lymph nodes
- tetanus toxoid (TT) 208–209
- thermosensitive liposomes 52–53
- thermosensitive polymer 46, 53
- tissues 153, 156, 302, 304, 389, 391–392, 395–396, 398, 404–405, 439, 465–466, 478, 480–481, 483, 525
 - distribution 106, 435
 - materials 482, 484
- topical application 533
- transdermal delivery 179
- trehalose 103–104, 338, 564
- TT, *see* tetanus toxoid
- tumor-associated antigens (TAAs) 322, 324
- tumor-associated macrophages (TAMs) 322–323, 329, 331–333
- tumor-bearing mice 129, 333, 440
- tumor cells 323, 332
- tumor-draining lymph nodes (TDLNs) 327
- tumor growth 69, 153, 155–156, 323, 332, 337

- tumor imaging 486
- tumor microenvironment 42, 331
- tumor regression 333
- tumors 40–42, 44–47, 53, 68, 70, 273–274, 303–304, 321–323, 325–329, 332–333, 466–467, 470–472, 477, 487–488, 560–562
 - human 560
 - mammary 273
 - xenograft 560
- tumor sites 276, 465, 467, 469, 471, 562
- tumor tissues 40, 42–45, 59, 62, 273, 323, 472
- ultrasonic waves 49–52, 272, 527, 531
- ultrasound 45–46, 50, 272, 277
- vaccines 66, 106, 205, 335–337, 365
- vasculature 41–42, 45, 466, 472–473, 482
- virus-like particles (VLPs) 334–335
- VLPs, *see* virus-like particles
- X-ray 465–466, 527
- zeta potential (ZP) 103, 403, 563
- ZP, *see* zeta potential

"The book is written in a lucid style, striking a good balance between medicine and chemistry. It is very well illustrated, contains numerous pertinent references, and provides an accessible and informative text, particularly for senior undergraduates, early-career researchers such as PhD students and postdocs, and others new to the subject of nanomedicine. It is a valuable addition to the literature of the growing field of nanomedicine, filling a previous need."

Prof. D. Ceri Davies
Imperial College London, UK

"This book is full of illustrations and helpful references. It not only is a perfect start for beginners, such as the university graduates, but also provides ample resources to more advanced researchers to progress further. Moreover, it presents a balanced critique of the topic while providing information from the perspectives of both chemistry and medicine."

Prof. Dimitri Scholz
University College Dublin, Ireland

"The author has written this book taking into consideration the very requirements of those working in healthcare. It is of great help for upcoming researchers and physicians exploring nanotechnology, especially as a quick reference guide. A vast subject has been succinctly and comprehensively put together in the book. Exercises at the end of each chapter are very useful to check the level of understanding."

Dr. K. Venkatesha Udupa
Oxford University Hospitals, UK

The scope of nanotechnology in medical applications has expanded fast in the last two decades. With their unprecedented material properties, nanoscale materials present with unorthodox opportunities in a wide range of domains, including drug delivery and medical imaging. This book assembles the various facets of nanomedicine while discussing key issues such as physicochemical properties that enhance the appeal of nanomedicine.

The book is an excellent resource for physicians, PhDs, and postdocs involved in nanomedicine research to learn and understand the scope and complexity of the subject. It begins with a short history of nanotechnology, followed by a discussion on the fundamental concepts and extraordinary properties of nanoscale materials, and then slowly unfolds into multiple chapters illustrating the uses of various nanomaterials in drug delivery, sensing, and imaging.



Sourav Bhattacharjee graduated in medicine (MBBS) in 2002 from the Medical College and Hospital, Kolkata, India, and obtained his MSc in biomolecular sciences from Vrije Universiteit (VU), Amsterdam, the Netherlands, in 2008 while performing his major thesis work on investigating the pulmonary toxicity of airborne nanoparticulate materials in Edinburgh, UK. He obtained his PhD (2008–2012) in nanomedicine and nanotoxicology from Wageningen University, the Netherlands. Dr. Bhattacharjee joined University College Dublin (UCD), Ireland, as a postdoc in 2014. In February 2016, he was appointed assistant professor at UCD, where he teaches anatomy while continuing to conduct research in nanomedicine, drug delivery, and biophotonics.



JENNY STANFORD
PUBLISHING

